

109TH CONGRESS
1ST SESSION

S. 2115

To amend the Public Health Service Act to improve provisions relating to Parkinson’s disease research.

IN THE SENATE OF THE UNITED STATES

DECEMBER 15, 2005

Ms. STABENOW (for herself, Mr. SMITH, Mr. LAUTENBERG, Mrs. MURRAY, Mr. MCCAIN, Mr. COLEMAN, and Mr. DAYTON) introduced the following bill; which was read twice and referred to the Committee on Health, Education, Labor, and Pensions

A BILL

To amend the Public Health Service Act to improve provisions relating to Parkinson’s disease research.

1 *Be it enacted by the Senate and House of Representa-*
2 *tives of the United States of America in Congress assembled,*

3 **SECTION 1. SHORT TITLE.**

4 This Act may be cited as the “Morris K. Udall Par-
5 kinson’s Disease Research Act Amendments of 2005”.

6 **SEC. 2. MORRIS K. UDALL PARKINSON’S DISEASE RE-**
7 **SEARCH ACT OF 1997.**

8 (a) FINDINGS.—Subsection (b) of section 603 of the
9 Morris K. Udall Parkinson’s Disease Research Act of

1 1977 (42 U.S.C. 284f note) is amended by striking para-
 2 graph (1) and inserting the following:

3 “(1) FINDING.—Congress finds that, to take
 4 full advantage of the tremendous potential for find-
 5 ing a cure or effective treatment, the Federal invest-
 6 ment in Parkinson’s must be expanded, as well as
 7 the coordination strengthened among the National
 8 Institutes of Health research institutes.”.

9 (b) PUBLIC HEALTH SERVICE ACT.—Section 409B
 10 of the Public Health Service Act (42 U.S.C. 284f) is
 11 amended—

12 (1) in subsection (b), by striking paragraph (2)
 13 and inserting the following:

14 “(2) CONFERENCE.—

15 “(A) IN GENERAL.—The Director of NIH
 16 shall convene a coordinating and planning con-
 17 ference every 2 years with relevant institutes
 18 and non-governmental organizations to conduct
 19 a thorough investigation of all Parkinson’s re-
 20 search that is funded in whole or in part by the
 21 National Institutes of Health and to identify
 22 shortcomings and opportunities for more effec-
 23 tive treatments and a cure for Parkinson’s dis-
 24 ease. The Director shall report to Congress on

1 the coordination among the institutes in car-
2 rying out such research.

3 “(B) RESEARCH INVESTMENT PLAN.—

4 “(i) IN GENERAL.—The results of
5 each conference convened under subpara-
6 graph (A) shall be included in a research
7 investment plan that provides for measur-
8 able results with the goals of better treat-
9 ments and a cure for Parkinson’s disease
10 being the determining factors in the alloca-
11 tion of Parkinson’s disease research dol-
12 lars. The plan shall include an outline of
13 the manner in which to fully utilize the
14 Udall Center program to ensure the con-
15 tinuation of a particular focus on
16 translational research, including a clinical
17 component.

18 “(ii) BUDGET AND IMPLEMENTATION
19 STRATEGY.—The plan submitted under
20 clause (i) shall include a budget (that in-
21 cludes both programmatic and dollar line
22 items) and implementation strategy (that
23 incorporates the use of special initiatives
24 such as Requests for Applications, Pro-
25 gram Announcements with set-asides or

similar directed research mechanisms) together with results to be reported back to Congress.

“(C) SUBMISSIONS TO CONGRESS.—The plan under subparagraph (B) (including the budget and implementation strategy) and the expected results of plan implementation shall be submitted to Congress not later than 3 months after the conference is convened under subparagraph (A). Reports on the outcomes of the plan, including actual spending and actual results, shall be submitted to Congress on an annual basis.

“(D) FUNDING.—The Secretary shall ensure that adequate funding is available under this section to carry out the activities described in the investment plan under subparagraph (B).”;

(2) in subsection (c)—

(A) in paragraph (1)—

(i) by striking “not more than 10”;

and

(ii) by adding at the end the following: “The Director shall ensure that an additional center shall be funded under

1 this paragraph to serve as the coordinating
 2 center to coordinate the activities con-
 3 ducted by each of the centers funded under
 4 this paragraph to further focus and man-
 5 age the interdisciplinary efforts of such
 6 centers.”;

7 (B) in paragraph (2)(A)(ii), by striking
 8 “conduct basic and clinical research” and in-
 9 serting “in carrying out research, ensure that a
 10 significant clinical component is provided for in
 11 addition to ongoing basic research”; and

12 (C) by adding at the end the following:

13 “(5) REVIEW PROCESS.—The Director of NIH
 14 shall establish a review process with respect to appli-
 15 cations received for grants under paragraph (1).
 16 Such process shall provide for the evaluation of ap-
 17 plicants in a manner that recognizes the unique as-
 18 pects of the clinical, coordination, and multidisci-
 19 plinary components of the applicants.”;

20 (3) in subsection (d)—

21 (A) by striking “is authorized to establish
 22 a grant program” and inserting “shall award
 23 grants”; and

24 (B) by inserting before the period at the
 25 end the following: “and shall be awarded in a

1 manner consistent with the research investment
2 plan under subsection (b)(2)(B)”; and
3 (4) by striking subsection (e) and inserting the
4 following:

5 “(e) REPORT.—The Director of NIH, in consultation
6 with the Director of the Centers for Disease Control and
7 Prevention, shall conduct an investigation, and prepare
8 and submit to the appropriate committees of Congress a
9 report, on the incidence of Parkinson’s disease, including
10 age, occupation, and geographic population clusters, and
11 related environmental factors relating to such disease.

12 “(f) AUTHORIZATION OF APPROPRIATIONS.—For the
13 purposes of carrying out this section, section 301, and this
14 title with respect to research focused on Parkinson’s dis-
15 ease, there are authorized to be appropriated not to exceed
16 such sums as may be necessary for each of fiscal years
17 2007 through 2012.”.

○